JP2007537295A5 - - Google Patents

Download PDF

Info

Publication number
JP2007537295A5
JP2007537295A5 JP2007513432A JP2007513432A JP2007537295A5 JP 2007537295 A5 JP2007537295 A5 JP 2007537295A5 JP 2007513432 A JP2007513432 A JP 2007513432A JP 2007513432 A JP2007513432 A JP 2007513432A JP 2007537295 A5 JP2007537295 A5 JP 2007537295A5
Authority
JP
Japan
Prior art keywords
disorder
compound
aliphatic
optionally substituted
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007513432A
Other languages
English (en)
Japanese (ja)
Other versions
JP5132305B2 (ja
JP2007537295A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/016902 external-priority patent/WO2005113541A1/en
Publication of JP2007537295A publication Critical patent/JP2007537295A/ja
Publication of JP2007537295A5 publication Critical patent/JP2007537295A5/ja
Application granted granted Critical
Publication of JP5132305B2 publication Critical patent/JP5132305B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007513432A 2004-05-14 2005-05-13 Ｅｒｋプロテインキナーゼのインヒビターとしてのピロール化合物、それらの合成、およびそれらの中間体 Expired - Lifetime JP5132305B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57130904P 2004-05-14 2004-05-14
US60/571,309 2004-05-14
PCT/US2005/016902 WO2005113541A1 (en) 2004-05-14 2005-05-13 Pyrrole compounds as inhibitors of erk protein kinase, synthesis thereof and intermediates thereto

Publications (3)

Publication Number Publication Date
JP2007537295A JP2007537295A (ja) 2007-12-20
JP2007537295A5 true JP2007537295A5 (https=) 2008-06-26
JP5132305B2 JP5132305B2 (ja) 2013-01-30

Family

ID=35106760

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007513432A Expired - Lifetime JP5132305B2 (ja) 2004-05-14 2005-05-13 Ｅｒｋプロテインキナーゼのインヒビターとしてのピロール化合物、それらの合成、およびそれらの中間体

Country Status (25)

Country Link
US (6) US7354939B2 (https=)
EP (5) EP2799434B1 (https=)
JP (1) JP5132305B2 (https=)
CN (1) CN1976919A (https=)
AR (2) AR051735A1 (https=)
AU (1) AU2005245885B2 (https=)
BR (1) BRPI0511111A (https=)
CA (1) CA2566461C (https=)
CY (1) CY1122336T1 (https=)
DK (1) DK3305776T3 (https=)
ES (4) ES2513965T3 (https=)
HU (1) HUE047130T2 (https=)
IL (1) IL179207A0 (https=)
LT (1) LT3305776T (https=)
MX (1) MXPA06013209A (https=)
NO (1) NO20065727L (https=)
NZ (1) NZ551582A (https=)
PL (1) PL3305776T3 (https=)
PT (1) PT3305776T (https=)
RU (1) RU2376299C2 (https=)
SI (1) SI3305776T1 (https=)
TW (1) TW200607803A (https=)
UA (1) UA84930C2 (https=)
WO (1) WO2005113541A1 (https=)
ZA (1) ZA200609975B (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004083203A1 (en) * 2003-03-13 2004-09-30 Vertex Pharmaceuticals Incorporated Compositions useful as protein kinase inhibitors
EP1730134A1 (en) * 2004-03-26 2006-12-13 Vertex Pharmaceuticals Incorporated Pyridine inhibitors of erk2 and uses thereof
LT3305776T (lt) * 2004-05-14 2020-01-10 Vertex Pharmaceuticals Incorporated Pirolo junginiai kaip erk baltymo kinazės inhibitoriai, ir farmacinės kompozicijos su šiais junginiais
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
MX2008010635A (es) 2006-02-16 2008-10-28 Schering Corp Derivados de pirrolidina como inhibidores de cinasa regulada por señales extracelulares.
AR068046A1 (es) * 2007-06-05 2009-11-04 Schering Corp Derivados policiclicos de indazol y su uso como inhibidores de erk para el tratamiento del cancer
WO2009105500A1 (en) 2008-02-21 2009-08-27 Schering Corporation Compounds that are erk inhibitors
CN102146074B (zh) * 2011-01-26 2013-02-06 江苏先声药物研究有限公司 吡咯衍生物的制备方法及应用
WO2012172093A1 (en) 2011-06-17 2012-12-20 Merz Pharma Gmbh & Co. Kgaa Dihydroindolizine derivate as metabotropic glutamate receptor modulators
EP3058371B1 (en) 2013-10-14 2021-06-16 Indiana University Research and Technology Corporation Use of acamprosate to modulate erk 1-2 activation in animal models for fxs and asd and individuals diagnosed with fxs and asd
US20160264536A1 (en) 2013-10-23 2016-09-15 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2015095835A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods of modulating radioiodine uptake for the treatment of radioiodine-refractory cancers
WO2015095842A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
WO2015095807A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of egfr and erk inhibitors
CA3240745A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatment using combinations of erk and raf inhibitors
JP6727127B2 (ja) * 2013-12-20 2020-07-29 バイオメッド バレー ディスカバリーズ，インコーポレイティド Ｐｉ３ｋ／ａｋｔシグナル経路阻害剤およびｅｒｋ阻害剤の組み合わせを使用するがん処置
JP6678583B2 (ja) * 2013-12-20 2020-04-22 バイオメッド バレー ディスカバリーズ，インコーポレイティド ２型ｍｅｋ阻害剤およびｅｒｋ阻害剤の組み合わせを用いるがん処置
WO2015095833A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Treatment of hematologic cancers
WO2015095831A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of mtor and erk inhibitors
AU2014368927B2 (en) * 2013-12-20 2018-10-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of CDK and ERK inhibitors
US20160310477A1 (en) * 2013-12-20 2016-10-27 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of mek type 1 and erk inhibitors
JP7180977B2 (ja) * 2015-01-30 2022-11-30 バイオメッド バレー ディスカバリーズ，インコーポレイティド 結晶性Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２マロン酸塩
AU2016211246B2 (en) * 2015-01-30 2020-08-27 Biomed Valley Discoveries, Inc. Crystalline forms of C21H22CI2N4O2
WO2016187028A1 (en) * 2015-05-15 2016-11-24 Celgene Avilomics Research, Inc. Heteroaryl compounds, synthesis thereof, and intermediates thereto
CN107849046B (zh) * 2015-06-03 2020-06-12 常州捷凯医药科技有限公司 作为erk抑制剂的杂环化合物
WO2016192064A1 (en) 2015-06-03 2016-12-08 Js Innopharm (Shanghai) Ltd. Heterocyclic compounds for treating psoriasis
EP3365334B1 (en) 2015-10-21 2024-07-17 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
EP3170822A1 (en) 2015-11-18 2017-05-24 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors
US10934304B2 (en) 2016-10-05 2021-03-02 Recurium Ip Holdings, Llc Spirocyclic compounds
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
JP7332589B2 (ja) * 2017-10-12 2023-08-23 ノバルティス アーゲー 癌を治療するためのｍｄｍ２阻害剤とｅｒｋの阻害剤との組合せ
WO2019180141A1 (en) 2018-03-23 2019-09-26 Bayer Aktiengesellschaft Combinations of rogaratinib
WO2020223177A1 (en) * 2019-04-29 2020-11-05 The Board Of Trustees Of The University Of Illinois Mek inhibitors for corneal scarring and neovascularization
WO2021020841A1 (en) * 2019-07-29 2021-02-04 Standigm Inc. Composition for preventing or treating metabolic liver disease
EP4212531A1 (en) 2022-01-14 2023-07-19 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors
CN118765276A (zh) * 2022-03-08 2024-10-11 甘李药业股份有限公司 氘代化合物，及其制备方法和应用
IL315702A (en) * 2022-03-24 2024-11-01 Biomed Valley Discoveries Inc Deuterated pyrrole inhibitory analogs of ERK, their synthesis and their intermediates

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US5565413A (en) * 1994-12-06 1996-10-15 Zeneca Limited Substituted pyridyl phenyl ketone herbicides
US5472966A (en) * 1995-03-29 1995-12-05 Bristol-Myers Squibb Company Antidepressant heteroarylaminoalkyl derivatives of naphthyl-monazines
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
WO2000069847A1 (en) * 1999-05-14 2000-11-23 Ortho-Mcneil Pharmaceutical, Inc. Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
ATE325114T1 (de) * 1999-06-22 2006-06-15 Takeda Pharmaceutical Acylhydrazinderivate, verfahren zu ihrer herstellung und ihre verwendung
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
AU2003237121A1 (en) * 2002-04-26 2003-11-10 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
CA2491895C (en) * 2002-07-09 2011-01-18 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
EP1546121B1 (en) * 2002-07-18 2012-08-29 Janssen Pharmaceutica NV Substituted triazine kinase inhibitors
GB0217780D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
MXPA05001804A (es) * 2002-08-14 2005-05-27 Vertex Pharma Inhibidores de proteinas cinasas y usos de los mismos.
WO2004083203A1 (en) 2003-03-13 2004-09-30 Vertex Pharmaceuticals Incorporated Compositions useful as protein kinase inhibitors
LT3305776T (lt) * 2004-05-14 2020-01-10 Vertex Pharmaceuticals Incorporated Pirolo junginiai kaip erk baltymo kinazės inhibitoriai, ir farmacinės kompozicijos su šiais junginiais

Similar Documents

Publication Publication Date Title
JP2007537295A5 (https=)
JP2010517990A5 (https=)
JP2007516714A5 (ja) 間葉系前駆細胞の骨芽細胞への分化を誘導する化合物の同定方法
JP2007521309A5 (https=)
JP2010519289A5 (https=)
JP2010539101A5 (https=)
RU2002107203A (ru) Производные N-гетероциклических соединений в качестве ингибиторов синтазы оксида азота (nos)
JP2008504265A5 (https=)
JP2007514047A5 (https=)
JP2002529532A5 (https=)
JP2009524691A5 (https=)
JP2002536300A5 (https=)
JP2020502268A5 (https=)
JP2001514282A5 (https=)
CN1246119A (zh) 吡咯并[3,4－d]－嘧啶酮衍生物及其作为药物的用途
JP2007511047A5 (https=)
JP2004502755A5 (https=)
JP2007506721A5 (https=)
JP2010517991A5 (https=)
JP2003514821A5 (https=)
JP2007537255A5 (https=)
JPWO2019141774A5 (https=)
JP2008526897A5 (https=)
JP2006526587A5 (https=)
CN106459108B (zh) 包含磷酰胆碱衍生物的分离材料